128 related articles for article (PubMed ID: 9820553)
21. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q.
Nauta AJ; Bottazzi B; Mantovani A; Salvatori G; Kishore U; Schwaeble WJ; Gingras AR; Tzima S; Vivanco F; Egido J; Tijsma O; Hack EC; Daha MR; Roos A
Eur J Immunol; 2003 Feb; 33(2):465-73. PubMed ID: 12645945
[TBL] [Abstract][Full Text] [Related]
22. Complement component C1q enhances invasion of human mononuclear phagocytes and fibroblasts by Trypanosoma cruzi trypomastigotes.
Rimoldi MT; Tenner AJ; Bobak DA; Joiner KA
J Clin Invest; 1989 Dec; 84(6):1982-9. PubMed ID: 2687332
[TBL] [Abstract][Full Text] [Related]
23. Chimeric synthetic peptides from the envelope (gp46) and the transmembrane (gp21) glycoproteins for the detection of antibodies to human T-cell leukemia virus type II.
Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
Biochem Biophys Res Commun; 2001 Nov; 289(1):7-12. PubMed ID: 11708768
[TBL] [Abstract][Full Text] [Related]
24. Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures.
Szabó J; Cervenák L; Tóth FD; Prohászka Z; Horváth L; Kerekes K; Beck Z; Bácsi A; Erdei A; Peerschke EI; Füst G; Ghebrehiwet B
Clin Immunol; 2001 May; 99(2):222-31. PubMed ID: 11318594
[TBL] [Abstract][Full Text] [Related]
25. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation.
Nauta AJ; Trouw LA; Daha MR; Tijsma O; Nieuwland R; Schwaeble WJ; Gingras AR; Mantovani A; Hack EC; Roos A
Eur J Immunol; 2002 Jun; 32(6):1726-36. PubMed ID: 12115656
[TBL] [Abstract][Full Text] [Related]
26. Human neutrophil peptide-1 inhibits both the classical and the lectin pathway of complement activation.
Groeneveld TW; Ramwadhdoebé TH; Trouw LA; van den Ham DL; van der Borden V; Drijfhout JW; Hiemstra PS; Daha MR; Roos A
Mol Immunol; 2007 Jul; 44(14):3608-14. PubMed ID: 17448537
[TBL] [Abstract][Full Text] [Related]
27. Characterization of envelope glycoprotein mutants for human T-cell leukemia virus type 1 infectivity and immortalization.
Tsukahara T; Wielgosz MM; Ratner L
J Virol; 2001 Oct; 75(19):9553-9. PubMed ID: 11533220
[TBL] [Abstract][Full Text] [Related]
28. Modular organization of the carboxyl-terminal, globular head region of human C1q A, B, and C chains.
Kishore U; Gupta SK; Perdikoulis MV; Kojouharova MS; Urban BC; Reid KB
J Immunol; 2003 Jul; 171(2):812-20. PubMed ID: 12847249
[TBL] [Abstract][Full Text] [Related]
29. Immunological risks of adult T-cell leukemia at primary HTLV-I infection.
Kannagi M; Ohashi T; Harashima N; Hanabuchi S; Hasegawa A
Trends Microbiol; 2004 Jul; 12(7):346-52. PubMed ID: 15223062
[TBL] [Abstract][Full Text] [Related]
30. Human T cell leukemia virus type I and neurologic disease: events in bone marrow, peripheral blood, and central nervous system during normal immune surveillance and neuroinflammation.
Grant C; Barmak K; Alefantis T; Yao J; Jacobson S; Wigdahl B
J Cell Physiol; 2002 Feb; 190(2):133-59. PubMed ID: 11807819
[TBL] [Abstract][Full Text] [Related]
31. Inhibitory effect of chondroitin sulfate type E on the binding step of human T-cell leukemia virus type 1.
Jinno-Oue A; Tanaka A; Shimizu N; Mori T; Sugiura N; Kimata K; Isomura H; Hoshino H
AIDS Res Hum Retroviruses; 2013 Mar; 29(3):621-9. PubMed ID: 23033806
[TBL] [Abstract][Full Text] [Related]
32. In vitro induction of HIV-1 replication in resting CD4(+) T cells derived from individuals with undetectable plasma viremia upon stimulation with human T-cell leukemia virus type I.
Moriuchi H; Moriuchi M
Virology; 2000 Dec; 278(2):514-9. PubMed ID: 11118373
[TBL] [Abstract][Full Text] [Related]
33. Human T lymphotropic virus types I and II proviral sequences in Argentinian blood donors with indeterminate Western blot patterns.
Mangano AM; Remesar M; del Pozo A; Sen L
J Med Virol; 2004 Oct; 74(2):323-7. PubMed ID: 15332282
[TBL] [Abstract][Full Text] [Related]
34. Rapid syncytium formation between human T-cell leukaemia virus type-I (HTLV-I)-infected T-cells and human nervous system cells: a possible implication for tropical spastic paraparesis/HTLV-I associated myelopathy.
Mor-Vaknin N; Turgeman H; Torgeman A; Wolfson M; Huleihel M; Aboud M
Cell Biol Int; 1998; 22(2):95-103. PubMed ID: 9878096
[TBL] [Abstract][Full Text] [Related]
35. Trypanosoma carassii calreticulin binds host complement component C1q and inhibits classical complement pathway-mediated lysis.
Oladiran A; Belosevic M
Dev Comp Immunol; 2010 Apr; 34(4):396-405. PubMed ID: 19913050
[TBL] [Abstract][Full Text] [Related]
36. Control of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Infection by Eliminating Envelope Protein-Positive Cells with Recombinant Vesicular Stomatitis Viruses Encoding HTLV-1 Primary Receptor.
Tezuka K; Okuma K; Kuramitsu M; Matsuoka S; Tanaka R; Tanaka Y; Hamaguchi I
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212930
[TBL] [Abstract][Full Text] [Related]
37. Antibody-independent neutralization of vesicular stomatitis virus by human complement. I. Complement requirements.
Mills BJ; Cooper NR
J Immunol; 1978 Oct; 121(4):1549-57. PubMed ID: 212482
[No Abstract] [Full Text] [Related]
38. Interaction of C1q and mannan-binding lectin with viruses.
Thielens NM; Tacnet-Delorme P; Arlaud GJ
Immunobiology; 2002 Sep; 205(4-5):563-74. PubMed ID: 12396016
[TBL] [Abstract][Full Text] [Related]
39. Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism.
Sullivan BL; Takefman DM; Spear GT
Virology; 1998 Sep; 248(2):173-81. PubMed ID: 9721226
[TBL] [Abstract][Full Text] [Related]
40. Interaction of the envelope glycoprotein of human immunodeficiency virus with C1q and fibronectin under conditions present in human saliva.
Su H; Boackle RJ
Mol Immunol; 1991 Aug; 28(8):811-7. PubMed ID: 1875953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
